Werewolf Therapeutics, Inc. 10-K — AI Bull & Bear Analysis

The 10-K paints a picture of a company in a race against time. On one side, the PREDATOR platform is showing genuine promise in solving the toxicity issues of cytokine therapy, potentially unlocking a massive market for safer immunotherapies. On the other, the financial reality is stark: Werewolf is a pre-revenue entity with a looming cash cliff and a fragile operational structure. Investors are essentially trading a high-quality scientific asset trapped within a distressed financial shell. The outcome hinges on whether the strategic review can secure a partnership or acquisition before the cash expires in late 2026. The convergence of the Q2 2026 clinical readouts and the August 2026 leadership milestones will determine if Werewolf is a breakthrough success or another cautionary tale of biotech volatility.